Literature DB >> 30190869

Low-dose brachytherapy strategies to treat uveal melanoma: is less more?

Patrick Oellers1, Prithvi Mruthyunjaya1.   

Abstract

The Collaborative Ocular Melanoma Study (COMS) has established equivalency of globe salvaging brachytherapy compared with enucleation in terms of survival for medium-sized choroidal melanoma. The radiation dose protocol followed by the COMS was 85 Gray to a prescription point of the tumor apex or 5 mm inner sclera; whichever was greater. While the COMS realized appropriate local and distant tumor control rates, ocular morbidity due to radiation complications remains a significant clinical challenge. Recent studies challenge the COMS radiation dose paradigm by demonstrating similar tumor control by utilizing lower radiation doses that are associated with reduced radiation toxicity. Improved operative techniques including intraoperative ultrasound can aid to obtain adequate radiation delivery to the tumor by ensuring optimal plaque position. Adjuvant transpupillary thermotherapy, intravitreal anti-VEGF and posterior sub-Tenon steroids may further enhance outcome by providing additional tumor control and/or facilitating visual recovery.

Entities:  

Keywords:  Collaborative Ocular Melanoma Study; Iodine-125; anti-VEGF; brachytherapy; choroidal melanoma; intraoperative ultrasound; low dose; photodynamic therapy; transpupillary thermotherapy; transvitreal biopsy

Year:  2016        PMID: 30190869      PMCID: PMC6094673          DOI: 10.2217/mmt.15.34

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN: 2045-0885


  54 in total

1.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19.

Authors:  Lee M Jampol; Claudia S Moy; Timothy G Murray; Sandra M Reynolds; Daniel M Albert; Andrew P Schachat; Kenneth R Diddie; Robert E Engstrom; Paul T Finger; Kenneth R Hovland; Leonard Joffe; Karl R Olsen; Craig G Wells
Journal:  Ophthalmology       Date:  2002-12       Impact factor: 12.079

2.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18.

Authors:  M Diener-West; J D Earle; S L Fine; B S Hawkins; C S Moy; S M Reynolds; A P Schachat; B R Straatsma
Journal:  Arch Ophthalmol       Date:  2001-07

3.  Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes.

Authors:  Bradford A Perez; Pradeep Mettu; Lejla Vajzovic; Douglas Rivera; Ali Alkaissi; Beverly A Steffey; Jing Cai; Sandra Stinnett; Jonathan J Dutton; Edward G Buckley; Edward Halperin; Lawrence B Marks; Prithvi Mruthyunjaya; David G Kirsch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-07       Impact factor: 7.038

4.  Mortality in patients with small choroidal melanoma. COMS report no. 4. The Collaborative Ocular Melanoma Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1997-07

5.  Factors predictive of growth and treatment of small choroidal melanoma: COMS Report No. 5. The Collaborative Ocular Melanoma Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1997-12

6.  Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects.

Authors:  Robert Jones; Elizabeth Gore; William Mieler; Kevin Murray; Michael Gillin; Katherine Albano; Beth Erickson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

7.  Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma.

Authors:  Karijn M S Verschueren; Carien L Creutzberg; Nicoline E Schalij-Delfos; Martijn Ketelaars; Floor L L Klijsen; Barbara I Haeseker; Sabine M B Ligtenberg; Jan E E Keunen; Corrie A M Marijnen
Journal:  Radiother Oncol       Date:  2010-04-21       Impact factor: 6.280

8.  Tumor-related lipid exudation after plaque radiotherapy of choroidal melanoma: the role of Bruch's membrane rupture.

Authors:  Arman Mashayekhi; Samuray Tuncer; Carol L Shields; Jerry A Shields
Journal:  Ophthalmology       Date:  2010-01-25       Impact factor: 12.079

9.  Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3.

Authors:  Michele Melia; Claudia S Moy; Sandra M Reynolds; James A Hayman; Timothy G Murray; Kenneth R Hovland; John D Earle; Natalie Kurinij; Li Ming Dong; Päivi H Miskala; Connie Fountain; David Cella; Carol M Mangione
Journal:  Arch Ophthalmol       Date:  2006-02

10.  Retinal break and rhegmatogenous retinal detachment after transpupillary thermotherapy as primary or adjunct treatment of choroidal melanoma.

Authors:  Arman Mashayekhi; Carol L Shields; Sung Chul Lee; Brian P Marr; Jerry A Shields
Journal:  Retina       Date:  2008-02       Impact factor: 4.256

View more
  1 in total

1.  Identification of 5 microRNA biomarkers associated with the prognosis of uveal melanoma.

Authors:  Yabin Sun; Xinmin Zhang; Zhongyi Cong; Siying Teng
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.